Document is current
Any future updates will be listed below
-
Authors
,
Taylor, John C. https://orcid.org/0000-0002-2518-5799
,
,
Bongartz, Tim
Massey, Jonathan
Mifsud, Borbala
Spiliopoulou, Athina https://orcid.org/0000-0002-5929-6585
Scott, Ian C.
Wang, Jianmei
Morgan, Michael
Plant, Darren
Colombo, Marco
Orchard, Peter
Twigg, Sarah
McInnes, Iain B.
Porter, Duncan
Freeston, Jane E.
Nam, Jackie L.
Cordell, Heather J.
Isaacs, John D.
Strathdee, Jenna L.
Arnett, Donna
de Hair, Maria J. H.
Tak, Paul P.
Aslibekyan, Stella
van Vollenhoven, Ronald F.
Padyukov, Leonid https://orcid.org/0000-0003-2950-5670
Bridges, S. Louis
Pitzalis, Costantino
Cope, Andrew P.
Verstappen, Suzanne M. M.
Emery, Paul
Barnes, Michael R. https://orcid.org/0000-0001-9097-7381
Agakov, Felix
McKeigue, Paul
Mushiroda, Taisei
Kubo, Michiaki
Weinshilboum, Richard
Barton, Anne https://orcid.org/0000-0003-3316-2527
Morgan, Ann W. https://orcid.org/0000-0003-1109-624X
Barrett, Jennifer H. https://orcid.org/0000-0002-1720-7724
- License Information
-
More Information
Article History
Received: 5 May 2017
Revised: 10 October 2017
Accepted: 9 February 2018
First Online: 25 May 2018
Compliance with ethical standards
:
: Paul P Tak is an employee and shareholder of GlaxoSmithKline; GSK has not been involved in this study. Jianmei Wang is an employee of Roche Products and Felix Agakov is an employee of Pharmatics Ltd., UK. Dr. Weinshilboum is a co-founder and stockholder in OneOme LLC, a Pharmacogenomics Decision Support Company. Paul Emery has undertaken clinical trials and provided expert advice to Pfizer, MSD, Abbvie, BMS, UCB, Roche, Novartis, Samsung, Sandoz and Lilly. The authors declare no conflict of interest with the content contained in this manuscript.
